Yeast strain and nitrogen supplementation: Dynamics of volatile ester production in Chardonnay juice fermentations

AC Miller, SR Wolff, LF Bisson… - American Journal of …, 2007 - Am Soc Enol Viticulture
Volatile esters are a major by-product in the yeast fermentation of grape juice and can
significantly impact wine flavor. Seven strains of Saccharomyces cerevisiae were monitored for …

[BOOK][B] The evolution of low molecular weight alcohols during wine fermentation: Effects of yeast strain ester productivity and nitrogen supplementation

SR Wolff - 2009 - search.proquest.com
Volatile, low molecular weight alcohols ranging in size from three to eight carbon atoms are
produced during yeast fermentation. Straight-chain, branched-chain and cyclic molecules …

Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial

…, R Bose, J Hu, D Weckstein, AC Wolff… - Journal of Clinical …, 2021 - ingentaconnect.com
PURPOSE The ATEMPT trial was designed to determine if treatment with trastuzumab
emtansine (T-DM1) caused less toxicity than paclitaxel plus trastuzumab (TH) and yielded …

[HTML][HTML] Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection

…, ZY Tang, B Klumpp, G Wolff-Vorbeck… - The Journal of …, 2002 - Am Soc Clin Investig
Hepatitis C virus (HCV) is a major cause of chronic hepatitis worldwide, but the study of HCV
infection has been hampered by the lack of an in vitro or in vivo small animal model. The …

[HTML][HTML] Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer …

…, T Mulvey, R Bose, J Hu, D Weckstein, AC Wolff… - NPJ Breast …, 2022 - nature.com
The excellent outcomes seen in patients treated with adjuvant trastuzumab emtansine (T-DM1)
in the ATEMPT trial and the favorable toxicity profile associated with this agent make T-…

Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) …

…, R Bose, T Sella, DJ Weckstein, AC Wolff… - Breast Cancer Research …, 2021 - Springer
Purpose Chemotherapy-related amenorrhea (CRA) is a surrogate for ovarian toxicity and
associated risk of infertility and premature menopause. Here, we compare CRA rate with …

[HTML][HTML] Human intestinal epithelial cells can internalize luminal fungi via LC3-associated phagocytosis

…, E Sadot, I White, N Wasserberg, M Wolff-Bar… - Frontiers in …, 2023 - frontiersin.org
Background Intestinal epithelial cells (IECs) are the first to encounter luminal microorganisms
and actively participate in intestinal immunity. We reported that IECs express the β-glucan …

Sharing in care: engaging care partners in the care and communication of breast cancer patients

JL Wolff, J Aufill, D Echavarria, JAA Heughan… - Breast cancer research …, 2019 - Springer
Purpose Family is often overlooked in cancer care. We developed a patient–family agenda
setting intervention to engage family in cancer care communication. Methods We conducted …

Telehealth delivery of cognitive-behavioral intervention to youth with autism spectrum disorder and anxiety: A pilot study

SL Hepburn, A Blakeley-Smith, B Wolff, JA Reaven - Autism, 2016 - journals.sagepub.com
Youth with autism spectrum disorders frequently experience significant symptoms of anxiety.
Empirically supported psychosocial interventions exist, yet access is limited, especially for …

Abstract PD10-02: patient reported outcomes from the adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel+ trastuzumab (TH)(ATEMPT) trial (TBCRC 033)

…, M Faggen, T Mulvey, R Bose, D Weckstein, A Wolff… - Cancer Research, 2020 - AACR
Purpose: The ATEMPT trial sought to determine if adjuvant T-DM1 (every 3 wks for 1 yr) for
Stage I HER2 positive breast cancer is better tolerated than TH (paclitaxel weekly x 12 wks …